| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | D584 |
| Uniprot No | Q03297 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1093aa |
| 氨基酸序列 | NKDKSRKKKKPKCIALATATAVSLEGTRESPLPASGSCEKVLQELQDTQQLGEPLVVTETQLSEQLLETEQNEDQNKSEQLAQFPLPTPIVTTLSPGIGPGHDCVGGASGGAVAGGCLVVGAGTDKTSELIPGKLESAGTKPSQERPKEESFCCVISMHDGIVLYTTPSISDVLGFPRDMWLGRSFVDFVHHKDRATFASQITTGIPIAESRGCMPKDARSTFCVMLRRYRGLNSGGFGVIGRAVNYEPFRLGLTFREAPEEARPDNYMVSNGTNMLLVICATPIKSSYKVPDEILSQKSPKFAIRHTATGIISHVDSAAVSALGYLPQDLIGRSIMDFYHHEDLSVMKDTYETVMKKGQTAGASFCSKPYRFLIQNGCFVLLETEWTSFVNPWSRKLEFVVGHHRVFQGPKLCNVFETSVSAKPKISEEAQNRNARIKEDIVKLLAETVSRPSDTVKQEVSRRCQALANFMETLMDEITRADLKLDLPHENELTVSERDSVMLGEISPHHDYYDSKSSTETPPSYNQLNYNENLLRFFNSKPVTAPVELDPPKVESSYVSSARGEDARSTLSPVQGFEGSGGSGSSGNFTTGSNLHMSSVTNTSNAGTGTSGTGNSGDGGGGGGADGTGSGAAPPVTLTESLLNKHNDEMEKFMLKKHRESRGRSGDKNKKSANEAMKMLEYSGPGPGHGHGIKRGGSHSWEGEANKPKQQLTLNTGGGGGGGGGGGGGGGGGLPLFLDVTHTSSSSQNKGPTGVAAGGAGGGVGGGGGSCSGLGGNGNVGSGNGNNSQPSTNQYTQSGLPCTQNINLWPPFSVGITTPTSVLSSHTAVPPSSFSPQHSLFPTFYYIPASIAASSPSSTNTNPNRPHKHAHVHSSSEKPSTSQAAAATMPLQYMTGVMYPHPSLFYTHPAAAAATAMVYQPVPFAGVANPMQLPEQASKNVYTTQPVMVAPPTATNKTQGAFHSITPAPPQRPSSQATSVKAETGSNVAPSDTSKKEVPDSPITPTMGDFTLDQPCNNNATTLKKYTDSNGNSDDMDGSSFSSFYSSFIKTTDGSESPPENDKDAKHRKLKSLDQSDNKIVEHPEEDQTQHG |
| 预测分子量 | 115 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于D584重组蛋白的3篇模拟参考文献(因D584重组蛋白可能为虚构或未广泛研究的蛋白名称，以下内容为示例性质，仅供参考)：
1. **文献名称**: "Expression and Functional Analysis of Recombinant D584 Protein in Cancer Immunotherapy"
**作者**: Li, X. et al.
**摘要**: 本研究通过大肠杆菌系统成功表达D584重组蛋白，并验证其在体外对T细胞的免疫激活作用。实验表明，D584可能通过增强抗原呈递抑制肿瘤生长。
2. **文献名称**: "Structural Characterization of D584 Recombinant Protein and Its Role in Viral Infection"
**作者**: Smith, J.R. & Wang, Y.
**摘要**: 作者利用X射线晶体学解析D584重组蛋白的三维结构，发现其与宿主细胞表面受体存在特异性结合，可能成为抗病毒药物的靶点。
3. **文献名称**: "D584 Recombinant Protein as a Diagnostic Marker for Autoimmune Diseases"
**作者**: Kumar, S. et al.
**摘要**: 研究开发了基于D584重组蛋白的ELISA检测方法，证实其在类风湿性关节炎患者血清中的高表达，提示其作为临床生物标志物的潜力。
---
**备注**：
如D584重组蛋白为实际研究对象，建议通过PubMed、Web of Science等平台，结合具体研究领域(如免疫学、结构生物学等)进行精准检索。若名称有误或需扩展，可提供更多关键词以便调整检索策略。
**Background of D584 Recombinant Protein**
D584 recombinant protein is a genetically engineered protein developed for research and therapeutic applications. It is typically produced using recombinant DNA technology, where the gene encoding the target protein is inserted into a host system (e.g., *E. coli*, yeast, or mammalian cells) to enable large-scale expression. The "D584" designation likely refers to a specific variant or mutation within the protein structure, possibly linked to functional domains, stability, or binding affinity. Such modifications are often introduced to optimize the protein's activity, solubility, or compatibility with downstream applications.
This protein may belong to a class of molecules involved in critical biological processes, such as immune regulation, signal transduction, or enzymatic activity. For instance, D584 could represent a cytokine, antibody fragment, or enzyme engineered for enhanced performance. Its recombinant nature ensures high purity and batch-to-batch consistency, making it valuable for structural studies, drug discovery, or diagnostic assays.
In therapeutic contexts, D584 recombinant protein might be explored for targeting specific pathways in diseases like cancer, autoimmune disorders, or infectious diseases. Preclinical studies often focus on its efficacy, pharmacokinetics, and safety profile. Additionally, its use in *in vitro* research aids in elucidating molecular mechanisms or validating drug targets.
The development of D584 reflects advancements in protein engineering and biomanufacturing, emphasizing tailored designs to meet experimental or clinical needs. Further characterization, including structural analysis (e.g., X-ray crystallography) and functional assays, is essential to fully understand its potential applications and limitations.
×
